ライフサイエンスコーパス: systemic therapy

1 s when docetaxel + trastuzumab was used as a systemic therapy.

2 safely undergo surveillance before starting systemic therapy.

3 phy was predominantly the result of improved systemic therapy.

4 ssive mCRPC immediately prior to new line of systemic therapy.

5 e fluocinolone acetonide implant or standard systemic therapy.

6 outcome in patients with advanced HCC before systemic therapy.

7 influence the timing of surgery relative to systemic therapy.

8 itivity within weeks following initiation of systemic therapy.

9 f strategy A over strategy C was the cost of systemic therapy.

10 fore and after the completion of neoadjuvant systemic therapy.

11 lay (sometimes indefinitely) the delivery of systemic therapy.

12 uable disease, who had not received previous systemic therapy.

13 rmatory diagnostic testing before initiating systemic therapy.

14 er during or at the completion of first-line systemic therapy.

15 search was restricted to articles evaluating systemic therapy.

16 long plasma circulation, which is useful for systemic therapy.

17 proliferating infantile hemangioma requiring systemic therapy.

18 cancer with progression on hormonal and one systemic therapy.

19 after discontinuation of the drug and use of systemic therapy.

20 go complete resection after combined HAI and systemic therapy.

21 s been referred for consideration of further systemic therapy.

22 e NSCLC tumors that had been resected before systemic therapy.

23 months (mean, 131 months) after cessation of systemic therapy.

24 from the operation and proceeded to further systemic therapy.

25 ed acute GVHD were eligible if they required systemic therapy.

26 hepatocellular carcinoma (HCC) without prior systemic therapy.

27 tatic cancer as a consolidative partner with systemic therapy.

28 o undergo lumpectomy, radiotherapy (RT), and systemic therapy.

29 iasis who are candidates for phototherapy or systemic therapy.

30 nced in patients with suboptimal response to systemic therapy.

31 fore and after the completion of neoadjuvant systemic therapy.

32 l sanctuaries in the context of conventional systemic therapy.

33 irst 2 years compared with those assigned to systemic therapy.

34 atients (62%) were initially treated without systemic therapy.

35 metastatic breast cancer who were receiving systemic therapy.

36 were observed in 15 patients, all receiving systemic therapy.

37 patients could be initially managed without systemic therapy.

38 ecur and target this population for adjuvant systemic therapy.

39 ed with regional therapy and avoid delays in systemic therapy.

40 DLS/DDLS who had progressive disease despite systemic therapy.

41 nts were randomized to either FA implants or systemic therapy.

42 tinum compounds represent the cornerstone of systemic therapy.

43 1969-2003) and after (2004-2014) advances in systemic therapy.

44 th cGVHD after failure of 1 or more lines of systemic therapy.

45 s when docetaxel + trastuzumab was used as a systemic therapy.

46 mphocytic leukaemia (CLL) who do not require systemic therapy.

47 well owing to the widespread use of adjuvant systemic therapy.

48 hs occurred after 15 years in the absence of systemic therapy.

49 f strategy A over strategy C was the cost of systemic therapy.

50 orubicin administration method, and previous systemic therapy.

51 A) to guide decisions on the use of adjuvant systemic therapy.

52 patients who had undergone previous local or systemic therapy.

53 were conducted in patients who also received systemic therapy.

54 ancer who are deemed candidates for adjuvant systemic therapy.

55 ntial whole-breast irradiation, and adjuvant systemic therapy.

56 n who did not receive the indicated adjuvant systemic therapy.

57 r guiding decisions on the need for adjuvant systemic therapy.

58 with breast-conserving therapy and adjuvant systemic therapy.

59 ration can decrease the benefit of cytotoxic systemic therapies.

60 vival, particularly in patients treated with systemic therapies.

61 ts were enrolled, with a median of two prior systemic therapies.

62 dertaken, with 198 MF/SS patients undergoing systemic therapies.

63 o GVHD treatment, and 14 of 17 required >/=2 systemic therapies.

64 All patients had received multiple previous systemic therapies.

65 Incidence of HZ associated with systemic therapies.

66 treatment regimens, including a median of 4 systemic therapies.

67 meet the criteria of surrogacy with specific systemic therapies.

68 gnosis and in helping to assess responses to systemic therapies.

69 onsible for the poor response of patients to systemic therapies.

70 uncover biomarkers predictive of response to systemic therapies.

71 ct, on the basis of incidence and benefit of systemic therapies.

72 between the 2 treatment groups (implant vs. systemic therapy, 2 letters; 95% CI, -10 to 15 letters;

73 teen patients were using a self-administered systemic therapy; 22.4% were classified as "non-adherent

74 visual acuity from baseline (implant, 61.7; systemic therapy, 65.0) through 7 years (implant, 55.8;

75 erapy, 65.0) through 7 years (implant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2

76 uveitic eyes (71% of 90 patients assigned to systemic therapy) (77% female; median age at enrollment,

77 rized and considered in terms of customizing systemic therapy according to biomarker (ERCC1 and RRM1)

78 reviously developed to assess the quality of systemic therapy across four domains (access, treatment

79 implants were not significantly better than systemic therapy (adjusted HR for progression, 0.5; P =

80 As systemic therapy advances provide better control of dist

81 is interest in the use of AC, the benefit of systemic therapy after neoadjuvant chemoradiation and es

82 assigned (1:1) to receive standard adjuvant systemic therapy alone (control group) or with zoledroni

83 wed by adjuvant systemic therapy relative to systemic therapy alone for patients with breast cancer l

84 ndomly assigned to receive standard adjuvant systemic therapy alone or with zoledronate administered

85 st-effectiveness of strategy B (conventional systemic therapy alone).

86 st-effectiveness of strategy B (conventional systemic therapy alone).

87 oved to be cost-effective when compared with systemic therapy alone, particularly in estrogen recepto

88 oved to be cost-effective when compared with systemic therapy alone, particularly in estrogen recepto

89 y may have greater therapeutic efficacy than systemic therapy alone.

90 vitreal foscarnet may be more effective than systemic therapy alone.

91 metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group

92 ymal stromal cell therapy as alternatives to systemic therapies and antibiotics for patients with inf

93 carriage, all of whom had received antenatal systemic therapy and 2 during the first trimester.

94 the brain, which complicates decisions about systemic therapy and assessments of survivorship outcome

95 e base covered questions related to adjuvant systemic therapy and included a systematic review conduc

96 led, all with liver metastases refractory to systemic therapy and ineligible for surgical resection.

97 ravitreous fluocinolone acetonide implant vs systemic therapy and long-term visual and other outcomes

98 in BSRC, which underscore the importance of systemic therapy and offer new insights into the potenti

99 nd stratified according to duration of prior systemic therapy and presence of liver metastases.

100 portantly, therapeutic advances in multidrug systemic therapy and radiation therapy have already been

101 Other treatments such as systemic therapy and radiation were used in remaining pa

102 luding the lack of suitable targets for safe systemic therapy and the need to achieve effective T cel

103 mes were obtained in the groups treated with systemic therapy and topical tacrolimus.

104 orbidity, the introduction of new, effective systemic therapies, and the improvement in survival time

105 They often require a systemic therapy, and ciclosporine A (CsA) is the only m

106 2 or less, had received standard first-line systemic therapy, and had no disease progression before

107 s after brain radiotherapy and HER2-targeted systemic therapy are a difficult therapeutic challenge.

108 Reductions in systemic therapy are possible, although radiation therap

109 Trials of systemic therapy are warranted in high-risk patients.

110 essed (P < 0.016), although most eyes in the systemic therapy arm also showed substantial improvement

111 ients with autoimmune diseases that required systemic therapy at screening were excluded from the stu

112 The number of systemic therapies available to treat LMS has increased

113 a patient is not a candidate for surgery or systemic therapy because of severe comorbid conditions,

114 by assigned treatment (129 implants vs. 126 systemic therapies) because of substantial differences i

115 Other options include systemic therapy, best supportive care, enrollment onto

116 In contrast to systemic therapy, bile acid release during a meal select

117 to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 1985-2012 a

118 ups held strong beliefs about their need for systemic therapy but differed in levels of medication co

119 plant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2 (95% CI, 2.1-12) letters.

120 oved to be a preferable adjunct agent to the systemic therapy by preventing both the local and system

121 n BSRC patients with active disease naive to systemic therapy compared with that of controls.

122 ease following one or more previous lines of systemic therapy consisting of at least two cycles of a

123 and also negatively affects the delivery of systemic therapy, contributes to morbidity of cancer tre

124 ere treated with 1 or more of the following: systemic therapy (corticosteroids or other immunosuppres

125 ed FU plus LV with a potentially more active systemic therapy could further improve overall survival.

126 acting OS, whereas discrepancies in adjuvant systemic therapies did not impact LR, DM, or OS of leiom

127 It may offer superior potential for systemic therapy, due to its improved tumor selectivity,

128 linicians when choosing between non-biologic systemic therapies, etanercept, adalimumab, and ustekinu

129 ing ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1

130 No effective systemic therapy exists for patients with metastatic low

131 postoperative radiotherapy with and without systemic therapy following primary surgery of OPSCC, ind

132 estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-m

133 Advances in systemic therapies for breast cancer have not substantiv

134 Available systemic therapies for CTCL may variably decrease tumor

135 Systemic therapies for inflammatory bowel disease are as

136 Use of systemic therapies for moderate to severe psoriasis in c

137 Effective systemic therapies for patients with advanced, progressi

138 atients with melanoma and clinical trials of systemic therapies for those with melanoma.

139 Current standard systemic therapies for treating breast cancer patients w

140 Here we review the landscape of systemic therapies for unresectable metastatic colorecta

141 breast cancer who had not received previous systemic therapy for advanced disease.

142 osine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (

143 Phase III randomized controlled trials of systemic therapy for advanced NSCLC between 1980 and 201

144 Purpose Systemic Therapy for Advanced or Metastatic Prostate Can

145 Systemic therapy for atopic dermatitis (AD) is indicated

146 Randomized clinical trials of neoadjuvant systemic therapy for breast cancer may help resolve this

147 ay reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized.

148 was reasonably cost-effective compared with systemic therapy for individuals with unilateral interme

149 gical margins) who had not received previous systemic therapy for melanoma from 91 hospitals located

150 es represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic

151 In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that c

152 Systemic therapy for metastatic melanoma has evolved rap

153 continued on observation until initiation of systemic therapy for metastatic renal-cell carcinoma; a

154 lacebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma.

155 ndations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-ce

156 published trials of neoadjuvant or adjuvant systemic therapy for prostate cancer.

157 half of patients with sarcoidosis will need systemic therapy for their disease.

158 Twenty patients received systemic therapy for widely disseminated disease.

159 set priorities for improving the quality of systemic therapy for women with early-stage breast cance

160 l therapy and matched controls not receiving systemic therapy from April 11, 2011, through June 30, 2

161 tus of 0 or 1, who had not received previous systemic therapy, from 43 sites worldwide.

162 Systemic therapy given for lymphoma after the first trim

163 s (median decrease of 180 vs. 109 mum in the systemic therapy group; P=0.04).

164 mulative 7-year incidence in the implant and systemic therapy groups, respectively, was less than 10%

165 , or panuveitis, those randomized to receive systemic therapy had better visual acuity than those ran

166 About 90% of patients with NOPR-planned systemic therapy had evaluation or management claims fro

167 ive chemoprevention strategies, and only one systemic therapy has been approved for patients with adv

168 not apply to the use of implant therapy when systemic therapy has failed or is contraindicated.

169 Systemic therapy has improved osteosarcoma event-free an

170 As the use of systemic therapy has increased and targeted therapies ha

171 ous cell carcinoma is a deadly disease where systemic therapy has relied upon empiric chemotherapy de

172 ted therapy against AXL, in combination with systemic therapies, has the potential to improve respons

173 coma, a disease in which currently available systemic therapies have proven inefficacious, with an em

174 es in locoregional therapies, radiation, and systemic therapies have provided better therapeutic opti

175 Whether advances in systemic therapies have rendered previously observed ben

176 BSRC patients with active disease naive to systemic therapy have elevated serum levels of 3 key imm

177 on score, Estrogen Receptor status, adjuvant systemic therapy, histology, and tumor size.

178 irst-line treatment, followed or replaced by systemic therapy if local therapy fails or cannot be per

179 should receive appropriate local therapy and systemic therapy, if indicated.

180 As systemic therapies improve, patients with lung cancer li

181 om NSCLC that did not progress after initial systemic therapy improved progression-free survival comp

182 parison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox pr

183 Successful development of targeted systemic therapies in DTC and MTC in the past 5 years is

184 efficacy exceeding those of other third-line systemic therapies in mCRPC patients.

185 entified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast

186 ct of NaF PET for monitoring the response to systemic therapies in such patients is unknown.

187 andomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical

188 We did a trial of dacomitinib as initial systemic therapy in clinically and molecularly selected

189 compared with patients who are treated with systemic therapy in isolation.

190 e-mode plans were much more often confirmed: systemic therapy in more than 85% of patients with ovari

191 maPrint assay to guide decisions on adjuvant systemic therapy in patients with hormone receptor-posit

192 Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell

193 ed to characterise the time to initiation of systemic therapy in patients with metastatic renal-cell

194 The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma r

195 pports the existence of impairment following systemic therapy in selected cognitive domains among som

196 enefit of hepatic radioembolization added to systemic therapy in the first- and second-line treatment

197 point of the study was time to initiation of systemic therapy in the per-protocol population.

198 The use of neoadjuvant systemic therapy in the treatment of breast cancer patie

199 nation, and volume regimens with and without systemic therapy in the treatment of OPSCC are outlined

200 Systemic therapies included plasmapheresis (18), chemoth

201 In contrast, potential complications of systemic therapy, including measures of hypertension, hy

202 There is increasing evidence that systemic therapy, including targeted therapy and immunot

203 ssessment of the cognitive effects of cancer systemic therapy into routine clinical practice.

204 The pipeline of more targeted topical and systemic therapies is expanding based on our growing und

205 r metabolic activity after the initiation of systemic therapy is an indicator of active disease, wher

206 recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a

207 d during transfection) have been used when a systemic therapy is indicated for large tumour burden an

208 d over the last decade, but the selection of systemic therapy is not based on the anatomic origin of

209 ve, especially for unilateral cases and when systemic therapy is not feasible or is not successful.

210 Following ocular therapy, adjuvant systemic therapy is provided for patients with high-risk

211 l suggesting that exploration of neoadjuvant systemic therapy is worthy of further investigation in r

212 Systemic therapies may be appropriate for young patients

213 ffectiveness and side-effect considerations, systemic therapy may be indicated as the initial treatme

214 ry, or who received preoperative/neoadjuvant systemic therapy may be offered SNB.

215 ry, or who received preoperative/neoadjuvant systemic therapy may be offered SNB.

216 estrogen-receptor status, type and timing of systemic therapy, menopausal status, statin use, and tre

217 estrogen receptor status, type and timing of systemic therapy, menopausal status, statin use, and tre

218 Nevertheless, with systemic therapy, most patients also experienced greatly

219 Systemic therapies must be considered carefully in light

220 Alternative systemic therapies need to be assessed in combination wi

221 assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer an

222 od-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of

223 ublished clinical trials and case reports on systemic therapy of pediatric and adult patients with AD

224 terminated the pregnancy to allow immediate systemic therapy; of the remaining 36 women, 24 received

225 out two-thirds monotherapy, of which 46% was systemic therapy only, and one-third combinations.

226 of successful randomized trials provides new systemic therapy options for patients with metastatic so

227 % CI = 0.60-1.41) compared with non-biologic systemic therapies or methotrexate-only (etanercept: HR

228 with severe psoriasis (defined as requiring systemic therapy or hospital admission): the risk ratio

229 were not treated with TNF inhibitors, other systemic therapies, or phototherapy (topical cohort).

230 value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic valu

231 mainly observed in patients not treated with systemic therapy (P < 0.01).

232 idisciplinary, involving surgery, radiation, systemic therapies, pathology, radiology, and other spec

233 Despite progress in locoregional and systemic therapies, patient survival from lung cancer re

234 Three trials on systemic therapy/phototherapy suggested that induction o

235 ogy), or the treatment (ie, poor response to systemic therapy, previous radiotherapy).

236 paid by 60 d confirmed the NOPR plan of any systemic therapy, radiotherapy, or surgery in 79.3%, 64.

237 Present systemic therapies rarely provide reliable and durable r

238 A systematic review of systemic therapy RCTs in STS was performed.

239 After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status,

240 ness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for

241 Participants who received only biologic systemic therapy reported improvement in physical health

242 n which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or dea

243 reatic cancer is extremely poor, and current systemic therapies result in only marginal survival rate

244 ommendations for confirmatory testing before systemic therapy should be reconsidered and replaced wit

245 Decisions regarding systemic therapy should not be made based on age alone.

246 axillary nodal involvement after neoadjuvant systemic therapy should receive PMRT.

247 e of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit f

248 re elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without

249 ction followed by postoperative conventional systemic therapy (strategy A) versus conventional therap

250 ction followed by postoperative conventional systemic therapy (strategy A) versus conventional therap

251 Systemic therapy subjects avoided a significant excess o

252 ay serve as a pharmacodynamic assessment for systemic therapy such as dasatinib, a potent SRC kinase

253 atment included a combination of topical and systemic therapies, such as corticosteroids, dapsone, is

254 isk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and

255 The same has been demonstrated with new systemic therapies (target therapies).

256 to 1 or 2 sentinel nodes, the radiation and systemic therapy that are part of modern multimodality b

257 on in LMS is surgery and despite progress in systemic therapy the outcome of patients with advanced/m

258 e, which sets the stage for consideration of systemic therapies to facilitate improved cell function

259 ndations Recommendations for the addition of systemic therapy to definitive radiotherapy in the treat

260 a manner that prioritizes early exposure to systemic therapy to maximize the treatment of micrometas

261 -cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at

262 For advanced HCC, sorafenib is the only systemic therapy to significantly prolong survival in pa

263 with breast-conserving surgery and adjuvant systemic therapy to undergo either whole-breast irradiat

264 influence surgical decisions and may affect systemic therapy trial eligibility, all young women with

265 for cancer patients 65 y or older receiving systemic therapy (use of 1 or more categories including

266 d non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psyc

267 clude locoregional therapies, radiation, and systemic therapy used alone or in combination with other

268 ortion of eyes with macular edema improving (systemic therapy vs. implant, 65% vs. 77%; P=0.20) and r

269 left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, sy

270 Median number of prior systemic therapies was 2 (range, 1-9), and 63% received

271 om registration on study until initiation of systemic therapy was 14.9 months (95% CI 10.6-25.0).

272 mean interval between diagnosis and starting systemic therapy was 3.0 years.

273 patients in 25 randomized trials of adjuvant systemic therapy was conducted.

274 l benefit of radical therapies compared with systemic therapy was even more pronounced (5-year surviv

275 Systemic therapy was not interrupted to perform the proc

276 treated patients (62% with two to five prior systemic therapies) was 16.8 months, and 1- and 2-year s

277 in all patients (71% with two to five prior systemic therapies) was 22.4 months; 1-, 2-, and 3-year

278 omatic patients with CLL who did not require systemic therapy were enrolled at MD Anderson Cancer Cen

279 Two or more categories of systemic therapy were planned in 56% of prostate and 43%

280 tive breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in Sou

281 procedures (e.g., laboratory monitoring for systemic therapy) were included.

282 were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational

283 d with strategy B when letrozole was used as systemic therapy, whereas it was only 0.3 QALMs when doc

284 d with strategy B when letrozole was used as systemic therapy, whereas it was only 0.3 QALMs when doc

285 C, following a prolonged period of induction systemic therapy, will be an area of intense scrutiny.

286 Thus, systemic therapy with activated MSC may be an effective

287 Systemic therapy with anti-VEGF drugs such as bevacizuma

288 ng in mind the potential risk of resistance, systemic therapy with antibiotics should be exclusively

289 Three patients underwent systemic therapy with diminution of the deposits and imp

290 gy procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or

291 He began systemic therapy with ipilimumab and nivolumab.

292 with stereotactic radiosurgery, and he began systemic therapy with ipilimumab on a clinical trial.

293 n patients with metastatic cancer undergoing systemic therapy with MEK inhibitors enrolled in clinica

294 ed comparative effectiveness trial comparing systemic therapy with oral corticosteroids and immunosup

295 an ultimately self-curing disease for which systemic therapy with pentavalent antimony (Sb) is effec

296 ments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-

297 d progressed after no more than one previous systemic therapy, with an Eastern Cooperative Oncology G

298 randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up.

299 ans for treatment (surgery, radiotherapy, or systemic therapy) within 90 d for lung and 180 d for pro

300 ur, the cost-effectiveness of implant versus systemic therapy would need to be reevaluated.